<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6059396</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0199167</article-id><article-id pub-id-type="publisher-id">PONE-D-18-00260</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Influenza</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject><subj-group><subject>H1N1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject><subj-group><subject>H1N1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject><subj-group><subject>H1N1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject><subj-group><subject>H1N1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Iodides</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Carbohydrates</subject><subj-group><subject>Monosaccharides</subject><subj-group><subject>Glucose</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Carbohydrates</subject><subj-group><subject>Monosaccharides</subject><subj-group><subject>Glucose</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Catalases</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Catalases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Susceptibility of influenza viruses to hypothiocyanite and hypoiodite produced by lactoperoxidase in a cell-free system</article-title><alt-title alt-title-type="running-head">Influenza inactivation by hypothiocyanite or hypoiodite</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Urmi</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Gingerich</surname><given-names>Aaron</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Widman</surname><given-names>Lauren</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-8306-0433</contrib-id><name><surname>Sarr</surname><given-names>Demba</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Tripp</surname><given-names>Ralph A.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9742-4955</contrib-id><name><surname>Rada</surname><given-names>Bal&#x000e1;zs</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="corresp" rid="cor001">*</xref><xref ref-type="aff" rid="aff001"/></contrib></contrib-group><aff id="aff001"><addr-line>University of Georgia, College of Veterinary Medicine, Department of Infectious Diseases, Athens, Georgia, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>P&#x000f6;hlmann</surname><given-names>Stefan</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Deutsches Primatenzentrum GmbH - Leibniz-Institut fur Primatenforschung, GERMANY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>radab@uga.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue>7</issue><elocation-id>e0199167</elocation-id><history><date date-type="received"><day>3</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>1</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Patel et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Patel et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0199167.pdf"/><abstract><p>Lactoperoxidase (LPO) is an enzyme found in several exocrine secretions including the airway surface liquid producing antimicrobial substances from mainly halide and pseudohalide substrates. Although the innate immune function of LPO has been documented against several microbes, a detailed characterization of its mechanism of action against influenza viruses is still missing. Our aim was to study the antiviral effect and substrate specificity of LPO to inactivate influenza viruses using a cell-free experimental system. Inactivation of different influenza virus strains was measured <italic>in vitro</italic> system containing LPO, its substrates, thiocyanate (SCN<sup>-</sup>) or iodide (I<sup>-</sup>), and the hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-producing system, glucose and glucose oxidase (GO). Physiologically relevant concentrations of the components of the LPO/H<sub>2</sub>O<sub>2</sub>/(SCN<sup>-</sup>/I<sup>-</sup>) antimicrobial system were exposed to twelve different strains of influenza A and B viruses <italic>in vitro</italic> and viral inactivation was assessed by determining plaque-forming units of non-inactivated viruses using Madin-Darby canine kidney cells (MDCK) cells. Our data show that LPO is capable of inactivating all influenza virus strains tested: H1N1, H1N2 and H3N2 influenza A viruses (IAV) and influenza B viruses (IBV) of both, Yamagata and Victoria lineages. The extent of viral inactivation, however, varied among the strains and was in part dependent on the LPO substrate. Inactivation of H1N1 and H1N2 viruses by LPO showed no substrate preference, whereas H3N2 influenza strains were inactivated significantly more efficiently when iodide, not thiocyanate, was the LPO substrate. Although LPO-mediated inactivation of the influenza B strains tested was strain-dependent, it showed slight preference towards thiocyanate as the substrate. The results presented here show that the LPO/H<sub>2</sub>O<sub>2</sub>/(SCN<sup>-</sup>/I<sup>-</sup>) cell-free, <italic>in vitro</italic> experimental system is a functional tool to study the specificity, efficiency and the molecular mechanism of action of influenza inactivation by LPO. These studies tested the hypothesis that influenza strains are all susceptible to the LPO-based antiviral system but exhibit differences in their substrate specificities. We propose that a LPO-based antiviral system is an important contributor to anti-influenza virus defense of the airways.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R21AI124189-01A1</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9742-4955</contrib-id><name><surname>Rada</surname><given-names>Bal&#x000e1;zs</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>University of Georgia OVPR</institution></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9742-4955</contrib-id><name><surname>Rada</surname><given-names>Bal&#x000e1;zs</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100008065</institution-id><institution>Georgia Research Alliance</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Tripp</surname><given-names>Ralph A.</given-names></name></principal-award-recipient></award-group><funding-statement>This work was mainly supported by the National Institutes of Health, National Institute of Allergy and Infectious Diseases R21AI124189-01A1 (Rada, Tripp), URL: <ext-link ext-link-type="uri" xlink:href="https://www.niaid.nih.gov">https://www.niaid.nih.gov</ext-link>; startup funds (Rada) provided by the Office of Vice President for Research, URL: <ext-link ext-link-type="uri" xlink:href="https://research.uga.edu">https://research.uga.edu</ext-link>; and the Georgia Research Alliance (Tripp), URL: <ext-link ext-link-type="uri" xlink:href="http://gra.org">http://gra.org</ext-link>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="8"/><table-count count="1"/><page-count count="17"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All data presented in the manuscript are openly shared. Plaque forming unit concentrations formed on MDCK cells of the virus strains tested in the report are deposited for each experiment in the Supporting Information Excel file organized according to the figure panels.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All data presented in the manuscript are openly shared. Plaque forming unit concentrations formed on MDCK cells of the virus strains tested in the report are deposited for each experiment in the Supporting Information Excel file organized according to the figure panels.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Influenza virus epidemics and periodic pandemics affect millions of people worldwide causing serious substantial morbidity and mortality representing a major economic burden [<xref rid="pone.0199167.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0199167.ref002" ref-type="bibr">2</xref>]. Current prophylactic options are problematic due to the yearly need for strain-specific vaccination, the development of drug resistance, and changes in the virus related to antigenic drift and viral reassortment [<xref rid="pone.0199167.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0199167.ref005" ref-type="bibr">5</xref>]. Identifying novel antiviral approaches that are broadly effective against several influenza strains is urgently needed. In this regard, the respiratory innate immune system could possess such mechanisms.</p><p>Bronchial epithelial cells (BEC) are a primary target for influenza virus replication [<xref rid="pone.0199167.ref006" ref-type="bibr">6</xref>]. Early response by BECs to influenza virus is crucial in determining progression of viral infection, adaptive immunity, and lung pathogenesis [<xref rid="pone.0199167.ref007" ref-type="bibr">7</xref>]. BECs orchestrate an oxidative extracellular antimicrobial system present in the airway surface liquid consisting of LPO, its main natural substrate, the thiocyanate anion (SCN<sup>-</sup>) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) (<xref ref-type="fig" rid="pone.0199167.g001">Fig 1</xref>) [<xref rid="pone.0199167.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0199167.ref011" ref-type="bibr">11</xref>]. LPO is an abundant peroxidase in the airways that uses H<sub>2</sub>O<sub>2</sub> to oxidize its most abundant and preferred substrate, SCN<sup>-</sup>, into hypothiocyanite (OSCN<sup>-</sup>) [<xref rid="pone.0199167.ref012" ref-type="bibr">12</xref>]. Hypothiocyanite is a short-lived, antimicrobial agent that is not toxic to the host and has been shown to kill several microbes, mainly bacteria. Its antiviral action remains, however, less characterized and understood.</p><fig id="pone.0199167.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0199167.g001</object-id><label>Fig 1</label><caption><title>Description of the cell-free <italic>in vitro</italic> experimental system producing antiviral hypothiocyanite or hypoiodite.</title><p>We established an <italic>in vitro</italic> experimental system to study the antiviral action of the LPO/H<sub>2</sub>O<sub>2</sub>/(SCN<sup>-</sup>/I<sup>-</sup>) system in the absence of epithelial cells. H<sub>2</sub>O<sub>2</sub> is generated in the enzymatic reaction of GO turning D-glucose into D-gluconate. Produced H<sub>2</sub>O<sub>2</sub> is used by LPO to oxidize its potential substrates, SCN<sup>-</sup> or I<sup>-</sup>. The products of the enzymatic action of LPO are either OSCN<sup>-</sup> or OI<sup>-</sup>, depending on the substrate used. Both, OSCN<sup>-</sup> or OI<sup>-</sup> have virucidal effects on influenza viruses. Physiologically relevant concentrations of LPO (6.5 &#x003bc;g/ml), SCN<sup>-</sup> or I<sup>-</sup> (400 &#x003bc;M), glucose (5 mM) and glucose oxidase (0.01 U/ml) are used. SCN<sup>-</sup>, thiocyanate; OSCN<sup>-</sup>, hypothiocyanite; I<sup>-</sup>, iodide; OI<sup>-</sup>, hypoiodite; LPO, lactoperoxidase; GO, glucose oxidase.</p></caption><graphic xlink:href="pone.0199167.g001"/></fig><p>Hypothiocyanite was to shown to inactivate the A/H1N1 2009 pandemic influenza virus in a cell-free system [<xref rid="pone.0199167.ref013" ref-type="bibr">13</xref>]. We also reported that OSCN<sup>-</sup> generated on the apical surface of BECs is capable of inactivating the A/swine/Illinois/02860/09 (swH1N2) influenza A strain [<xref rid="pone.0199167.ref009" ref-type="bibr">9</xref>]. These observations suggest that the H<sub>2</sub>O<sub>2</sub>/LPO/SCN<sup>-</sup> system is an important contributor to anti-influenza viral defense of the respiratory immune system, and imply that this innate response could be utilized to enhance early clearance of influenza virus perhaps in a strain-independent manner. To better understand the anti-influenza virus action of this oxidative system, we aimed at characterizing its virus-inactivating effect by testing several influenza virus strains. In addition to its natural substrate, SCN<sup>-</sup>, we also tested iodide (I<sup>-</sup>), as LPO substrate to study the substrate specificity of the antiviral action of LPO. LPO readily oxidizes several halides and pseudohalides using H<sub>2</sub>O<sub>2</sub> [<xref rid="pone.0199167.ref014" ref-type="bibr">14</xref>]. Iodide is considered to be a better LPO substrate than SCN<sup>-</sup> to inhibit growth of certain fungi and bacteria [<xref rid="pone.0199167.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0199167.ref016" ref-type="bibr">16</xref>]. In this study, we tested an <italic>in vitro</italic>, cell-free experimental system to characterize the anti-influenza virus action and substrate specificity of LPO. We found that LPO inactivates a wide-range of influenza strains, but surprisingly the extent of LPO-mediated viral inactivation and LPO substrate preference differed among tested isolates.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Influenza A and B strains</title><p>Influenza A and B strains used in this work were purchased from the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH (BEI Resources) and are listed in <xref rid="pone.0199167.t001" ref-type="table">Table 1</xref>. Influenza viruses were propagated in Madin-Darby Canine Kidney (MDCK) cells (ATCC&#x000ae; CCL-34&#x02122;) as described [<xref rid="pone.0199167.ref009" ref-type="bibr">9</xref>]. Briefly, MDCK cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing high glucose (HyClone) supplemented with 5% heat-inactivated fetal bovine serum (FBS; HyClone) and maintained at 37&#x000b0;C with 5% CO<sub>2</sub>. Viral strains were cultured in MDCK cells using infection medium (DMEM containing high glucose supplemented with 1 mM L-glutamine with 1-&#x003bc;g/ml tosylsulfonyl phenylalanyl chloromethyl ketone [TPCK]-treated trypsin). Viruses were collected 24&#x02013;48 hours post-infection.</p><table-wrap id="pone.0199167.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0199167.t001</object-id><label>Table 1</label><caption><title>Influenza virus strains used in this work.</title></caption><alternatives><graphic id="pone.0199167.t001g" xlink:href="pone.0199167.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Viral strain</th><th align="center" rowspan="1" colspan="1">Viral species</th><th align="center" rowspan="1" colspan="1">Serotype/subtype</th></tr></thead><tbody><tr><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1"><bold>A/Brisbane/59/2007</bold></td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">IAV</td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">H1N1</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>A/California/04/2009</bold></td><td align="center" rowspan="1" colspan="1">IAV</td><td align="center" rowspan="1" colspan="1">H1N1</td></tr><tr><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1"><bold>A/Mississippi/3/2001</bold></td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">IAV</td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">H1N1</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>A/Turkey/Kansas/4880/1980</bold></td><td align="center" rowspan="1" colspan="1">IAV</td><td align="center" rowspan="1" colspan="1">H1N1</td></tr><tr><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1"><bold>A/Swine/Illinois/02860/2009</bold></td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">IAV</td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">H1N2</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>A/Texas/50/2012</bold></td><td align="center" rowspan="1" colspan="1">IAV</td><td align="center" rowspan="1" colspan="1">H3N2</td></tr><tr><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1"><bold>A/Wisconsin/67/2005</bold></td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">IAV</td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">H3N2</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>A/Aichi/2/1968</bold></td><td align="center" rowspan="1" colspan="1">IAV</td><td align="center" rowspan="1" colspan="1">H3N2</td></tr><tr><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1"><bold>A/Hong Kong/8/1968</bold></td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">IAV</td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">H3N2</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>B/Yamagata/16/1988</bold></td><td align="center" rowspan="1" colspan="1">IBV</td><td align="center" rowspan="1" colspan="1">Yamagata</td></tr><tr><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1"><bold>B/Great Lakes/1739/1954</bold></td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">IBV</td><td align="center" style="background-color:#CCCCCC" rowspan="1" colspan="1">Yamagata</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>B/New York/1056/2003</bold></td><td align="center" rowspan="1" colspan="1">IBV</td><td align="center" rowspan="1" colspan="1">Victoria</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>IAV, Influenza A virus; IBV, Influenza B virus. Viruses were purchased from BEI Resources.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec004"><title>Cell-free viral inactivation assay</title><p>Components of the LPO-based antiviral system were used at the following concentrations: 6.5 &#x003bc;g/ml LPO, 400 &#x003bc;M SCN<sup>-</sup>/I<sup>-</sup>, glucose (0.005 M) and glucose oxidase 0.01 U/mL. The reaction volume was set to 40 &#x003bc;L with the appropriate concentration of each component mentioned above. Catalase (700 U/mL, Sigma-Aldrich, St. Louis, MO) was also used when indicated to inhibit the system. The components were assembled in a sterile Eppendorf tube with the virus being added last. The tubes were then placed on a 37&#x000b0;C heating block for one hour. After the incubation, supernatants were stored at -80&#x000b0;C. Plaque assays were performed on MDCK cells to determine viral concentrations as previously described [<xref rid="pone.0199167.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0199167.ref017" ref-type="bibr">17</xref>]. This assay is the &#x0201c;cell-free&#x0201d; version of the viral inactivation assay established previously on primary airway epithelial cells with the main difference that the source of H<sub>2</sub>O<sub>2</sub> here is the glucose/GO enzymatic reaction compared to Dual oxidase 1 in epithelial cells [<xref rid="pone.0199167.ref009" ref-type="bibr">9</xref>].</p></sec><sec id="sec005"><title>Statistics</title><p>Data for the viral inactivation assay were log<sub>10</sub>-transformed and significance was calculated using a one-way ANOVA followed by Tukey or Dunn&#x02019;s multiple comparison post-hoc test when more than two samples were compared. When virus inactivation or the substrate preference ratios were compared between two LPO substrates or influenza subtypes or species, Mann-Whitney test was used. Statistical analysis was performed using Prism 6 for Windows version 6.07 software. *, p&#x0003c;0.05; **, p&#x0003c;0.01; ***, p&#x0003c;0.001.</p></sec></sec><sec sec-type="results" id="sec006"><title>Results</title><sec id="sec007"><title>Optimization of the cell-free, in vitro H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) experimental system</title><p>LPO is produced by submucosal glands and epithelial cells in the respiratory tract and it accumulates in the airway surface liquid [<xref rid="pone.0199167.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0199167.ref019" ref-type="bibr">19</xref>]. LPO concentration in airway secretions has been estimated to be in the range of 3&#x02013;12 &#x003bc;g/ml [<xref rid="pone.0199167.ref018" ref-type="bibr">18</xref>]. We used a physiologically relevant LPO concentration of 6.5 &#x003bc;g/ml in our cell-free assay [<xref rid="pone.0199167.ref020" ref-type="bibr">20</xref>]. Thiocyanate is present in airway secretions in submillimolar concentrations [<xref rid="pone.0199167.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0199167.ref018" ref-type="bibr">18</xref>]. Accordingly, we used 400 &#x003bc;M SCN<sup>-</sup> in the <italic>in vitro</italic> assay, and used 400 &#x003bc;M iodide as alternative LPO substrate. The same LPO and SCN<sup>-</sup> concentrations were used as previously published in our prior studies using primary bronchial epithelial cells to make results comparable between the cell-free system and epithelial cultures [<xref rid="pone.0199167.ref009" ref-type="bibr">9</xref>]. While H<sub>2</sub>O<sub>2</sub> has been detected in airway secretions of humans and other mammalian species, estimating its basal levels is difficult due to its volatile nature. The main <italic>in vivo</italic> sources of H<sub>2</sub>O<sub>2</sub> in the airways are NADPH oxidases called Dual Oxidase 1 and 2 (Duox 1/2) [<xref rid="pone.0199167.ref008" ref-type="bibr">8</xref>]. Duox enzymes are highly expressed in the apical plasma membrane of BECs and generate H<sub>2</sub>O<sub>2</sub> directly into the airway surface liquid [<xref rid="pone.0199167.ref008" ref-type="bibr">8</xref>]. In our <italic>in vitro</italic> system containing BECs, Duox enzymes generate H<sub>2</sub>O<sub>2</sub> driving the antimicrobial action of LPO [<xref rid="pone.0199167.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0199167.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0199167.ref021" ref-type="bibr">21</xref>]. In the cell-free system described here, H<sub>2</sub>O<sub>2</sub> is provided by the enzymatic reaction of glucose (5 mM) and glucose oxidase (GO) that produces D-gluconic acid as the end product (<xref ref-type="fig" rid="pone.0199167.g001">Fig 1</xref>) [<xref rid="pone.0199167.ref020" ref-type="bibr">20</xref>]. Generating H<sub>2</sub>O<sub>2</sub> by an enzymatic reaction better models the slow but maintained nature and kinetics of H<sub>2</sub>O<sub>2</sub> release by BECs than a bolus-like addition of H<sub>2</sub>O<sub>2</sub> [<xref rid="pone.0199167.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0199167.ref021" ref-type="bibr">21</xref>]. To mimic the H<sub>2</sub>O<sub>2</sub> output of BECs in the cell-free system, we titrated the dose of GO and chose 0.01 U/ml, a concentration that is the closest to the hourly H<sub>2</sub>O<sub>2</sub> production of BECs [<xref rid="pone.0199167.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0199167.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0199167.ref021" ref-type="bibr">21</xref>] (data not shown). Thus, the components of the cell-free system are used in concentrations that are physiologically relevant.</p></sec><sec id="sec008"><title>The cell-free H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system inactivates the A/Swine/Illinois/02860/2009 H1N2 influenza virus</title><p>We have shown previously that BECs are capable of inactivating the A/Swine/Illinois/02860/2009 (H1N2) influenza A strain (<xref rid="pone.0199167.t001" ref-type="table">Table 1</xref>) in a H<sub>2</sub>O<sub>2</sub> (Duox)-, LPO- and SCN<sup>&#x02014;</sup>dependent manner [<xref rid="pone.0199167.ref009" ref-type="bibr">9</xref>]. Next we wanted to confirm this in the cell-free system. As shown in <xref ref-type="fig" rid="pone.0199167.g002">Fig 2A</xref>, the H<sub>2</sub>O<sub>2</sub>/LPO/SCN<sup>-</sup> cell-free system had also a strong and substantial inactivating effect on the A/Swine/Illinois/02860/2009 (H1N2) strain. Importantly, viral inactivation in the cell-free system was entirely blocked by the addition of catalase, a H<sub>2</sub>O<sub>2</sub>-scavanging enzyme (<xref ref-type="fig" rid="pone.0199167.g002">Fig 2A</xref>). No viral inactivation was observed when only GO was added but LPO and SCN<sup>-</sup> were omitted from the system (<xref ref-type="fig" rid="pone.0199167.g002">Fig 2A</xref>). Similarly, having LPO and SCN<sup>-</sup> without the H<sub>2</sub>O<sub>2</sub>-generating GO had no substantial viral-inactivating effect (<xref ref-type="fig" rid="pone.0199167.g002">Fig 2A</xref>). Comparable data were observed on BECs [<xref rid="pone.0199167.ref009" ref-type="bibr">9</xref>] indicating that H<sub>2</sub>O<sub>2</sub> alone is inefficient and OSCN<sup>-</sup> is responsible for inactivating the H1N2 influenza strain in both systems.</p><fig id="pone.0199167.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0199167.g002</object-id><label>Fig 2</label><caption><title>The cell-free H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system inactivates A/Swine/Illinois/02860/2009 H1N2 influenza A virus.</title><p>The antiviral action of the cell-free H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system was tested against the A/Swine/Illinois/02860/2009 (H1N2) influenza A virus. Viruses were incubated in the presence or absence of the components of the cell-free system as indicated for 1 hour when (A) SCN<sup>-</sup> or (B) I<sup>-</sup> was used as LPO substrate. Viral inactivation was assessed by plate-forming unit assay using MDCK cells. Mean+/-S.E.M., n = 4&#x02013;5. (C) SCN<sup>-</sup> and I<sup>-</sup> dose-dependence of A/Swine/Illinois/02860/2009 inactivation. Mean+/-S.E.M., n = 3. One-way ANOVA, Tukey&#x02019; multiple comparison test. Ns, non-significant, **, p&#x0003c;0.01; ***, p&#x0003c;0.001. SCN<sup>-</sup>, thiocyanate; OSCN<sup>-</sup>, hypothiocyanite; I<sup>-</sup>, iodide; OI<sup>-</sup>, hypoiodite; LPO, lactoperoxidase; GO, glucose oxidase; MDCK, Madin-Darby canine kidney cells; PFU, plaque-forming unit.</p></caption><graphic xlink:href="pone.0199167.g002"/></fig><p>Next, we tested how H1N2 inactivation by the cell-free system changes if I<sup>-</sup> (an alternative LPO substrate) is used. I<sup>-</sup> has been shown to enhance the antiviral activity of LPO against adenovirus and respiratory syncytial viruses [<xref rid="pone.0199167.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0199167.ref022" ref-type="bibr">22</xref>]. I<sup>-</sup> was used at the same concentration as SCN<sup>-</sup> (400 &#x003bc;M). Replacing SCN<sup>-</sup> with I<sup>-</sup> in the cell-free system led to even more effective H1N2 inactivation (<xref ref-type="fig" rid="pone.0199167.g002">Fig 2A</xref>). Similar to results obtained with SCN<sup>-</sup>, catalase blocked viral inactivation when I<sup>-</sup> was used (<xref ref-type="fig" rid="pone.0199167.g002">Fig 2B</xref>). Omitting any of the components of the I<sup>&#x02014;</sup>based cell-free system resulted in complete loss of H1N2 inactivation confirming that hypoiodite (OI<sup>-</sup>) is responsible for the virucidal effect (<xref ref-type="fig" rid="pone.0199167.g002">Fig 2B</xref>). To better characterize the substrate preference of LPO in inactivating H1N2, we tested viral inactivation at doses of SCN<sup>-</sup> and I<sup>-</sup> lower than 400 &#x003bc;M. As the dose-dependence curves shown in <xref ref-type="fig" rid="pone.0199167.g002">Fig 2C</xref> indicate, H1N2 was more susceptible to I<sup>&#x02014;</sup>mediated inactivation by the cell-free system. Interestingly, sensitivity to OSCN<sup>-</sup> drops drastically at SCN<sup>-</sup> doses just below 100 &#x003bc;M (<xref ref-type="fig" rid="pone.0199167.g002">Fig 2C</xref>). Results presented here confirm that the cell-free system serves as a good model to study influenza inactivation by the H<sub>2</sub>O<sub>2</sub>/LPO/SCN<sup>-</sup> system, and the swine H1N2 strain tested is susceptible to both, OSCN<sup>-</sup> and OI<sup>&#x02014;</sup>mediated inactivation by LPO, with a slightly higher sensitivity to OI<sup>-</sup>.</p></sec><sec id="sec009"><title>H1N1 influenza A strains are inactivated by LPO in a substrate-independent manner</title><p>Influenza A viruses are classified based on two of their surface proteins, hemagglutinin (HA) and neuraminidase (NA), that also determine their antigenic specificities. Since the H1N1 and H3N2 serotypes have been commonly present in human epidemics and pandemics over the last century [<xref rid="pone.0199167.ref023" ref-type="bibr">23</xref>], it was important to compare several H1N1 and H3N2 strains in the cell-free system for LPO-mediated inactivation (<xref rid="pone.0199167.t001" ref-type="table">Table 1</xref>). The IAV H1N1 strains, A/Brisbane/59/2007, A/California/04/2009 and A/Mississippi/3/2001 (<xref rid="pone.0199167.t001" ref-type="table">Table 1</xref>), cause seasonal influenza virus infections in humans while the A/Turkey/Kansas/4880/1980 H1N1 strain is a virus of swine antigenic phenotype isolated from turkeys [<xref rid="pone.0199167.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0199167.ref025" ref-type="bibr">25</xref>]. We tested A/Brisbane/59/2007 and observed a 1.31+/-0.42 (mean+/-S.E.M., n = 3) log (SCN<sup>-</sup>) and a 1.06+/-0.28 (mean+/-S.E.M., n = 3) log (I<sup>-</sup>) inactivation by the cell-free system, respectively (<xref ref-type="fig" rid="pone.0199167.g003">Fig 3A</xref>). The extent of OSCN<sup>&#x02014;</sup>mediated viral inactivation was significant (p = 0.011) while that of OI<sup>-</sup> was not (p = 0.090) (<xref ref-type="fig" rid="pone.0199167.g003">Fig 3A</xref>). Catalase had an inhibitory but non-significant (p = 0.092) and incomplete effect on viral inactivation for both substrates (<xref ref-type="fig" rid="pone.0199167.g003">Fig 3A</xref>). Both LPO substrates mediated A/California/04/2009 viral inactivation beyond detection limit of the assay in the cell-free system which was highly significant (p&#x0003c;0.0001, for each substrate) (<xref ref-type="fig" rid="pone.0199167.g003">Fig 3A</xref>). Removing H<sub>2</sub>O<sub>2</sub> by catalase treatment significantly reversed (p&#x0003c;0.0001) the virus-inactivating effect of LPO by both substrates (<xref ref-type="fig" rid="pone.0199167.g003">Fig 3A</xref>). The A/Mississippi/3/2001 strain was also efficiently inactivated by LPO in a substrate-independent manner (log-based extent of inactivation: 6.16+/-0.27 for OSCN<sup>-</sup> while 6.88+/-0.55 for OI<sup>-</sup>, n = 4) that was entirely blocked by catalase (<xref ref-type="fig" rid="pone.0199167.g003">Fig 3A</xref>). Although the A/Turkey/Kansas/4880/1980 H1N1 strain was also efficiently inactivated by LPO, its extent did not reach levels of significance (<xref ref-type="fig" rid="pone.0199167.g003">Fig 3A</xref>). While the four H1N1 influenza strains tested did not show a strong substrate preference in terms of inactivation by the cell-free H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system, they differed in their susceptibilities (<xref ref-type="fig" rid="pone.0199167.g003">Fig 3A</xref>). This is also shown in <xref ref-type="fig" rid="pone.0199167.g003">Fig 3B</xref> where the extent of virus inactivation is calculated as the catalase-dependent difference in viable viral titers (viral doses detected in presence of the full cell-free system are subtracted from viral doses recovered in presence of the full cell-free system plus catalase). Virus inactivation is calculated throughout the entire manuscript the same way.</p><fig id="pone.0199167.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0199167.g003</object-id><label>Fig 3</label><caption><title>Hypoiodite and hypothiocyanite are equally efficient in inactivating H1N1 influenza A viruses in the cell-free system.</title><p>(A) The antiviral action of the cell-free H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system was tested against H1N1 influenza A strains, A/Brisbane/59/2007 (n = 3), A/California/04/2009 (n = 5), A/Mississippi/3/2001 (n = 4) and A/Turkey/Kansas/4880/1980 (n = 2). Viruses were incubated in the presence or absence of the components of the cell-free system as indicated for 1 hour and viral inactivation was assessed by plate-forming unit assay using MDCK cells. Mean+/-S.E.M. One-way ANOVA, Dunn&#x02019;s multiple comparison test. (B) No significant difference can be observed in virus inactivation of the four H1N1 strains tested. Virus inactivation is calculated as the difference in viable viral titers between the sample containing the cell-free system and the sample containing the full, cell-free system plus catalase. Mean+/-S.E.M., n = 2&#x02013;5. Mann-Whitney test. Ns, non-significant, *, p&#x0003c;0.05; **, p&#x0003c;0.01; ***, p&#x0003c;0.001. SCN<sup>-</sup>, thiocyanate; OSCN<sup>-</sup>, hypothiocyanite; I<sup>-</sup>, iodide; OI<sup>-</sup>, hypoiodite; LPO, lactoperoxidase; GO, glucose oxidase; MDCK, Madin-Darby canine kidney cells; PFU, plaque-forming unit; IAV, Influenza A virus.</p></caption><graphic xlink:href="pone.0199167.g003"/></fig></sec><sec id="sec010"><title>Iodide is the preferred LPO substrate to inactivate H3N2 IAV strains</title><p>H3N2 IAV strains have become dominant causes of recent seasonal influenza epidemics [<xref rid="pone.0199167.ref001" ref-type="bibr">1</xref>]. The following four H3N2 influenza A strains were tested in the cell-free system for their LPO substrate specificities: A/Texas/50/2012, A/Wisconsin/67/2005, A/Aichi/2/1968 and A/Hong Kong/8/1968 (<xref rid="pone.0199167.t001" ref-type="table">Table 1</xref>). These H3N2 strains circulate in the human population causing seasonal infections [<xref rid="pone.0199167.ref026" ref-type="bibr">26</xref>&#x02013;<xref rid="pone.0199167.ref029" ref-type="bibr">29</xref>]. As shown in <xref ref-type="fig" rid="pone.0199167.g004">Fig 4A</xref>, OSCN<sup>-</sup> treatment resulted in a decrease of infectious virus titers as measured by plaque assay between 1&#x02013;3 logs for these H3N2 strains. While OSCN<sup>&#x02014;</sup>mediated inactivation of A/Texas/50/2012 (p = 0.049) and A/Wisconsin/67/2005 (p = 0.023) were significant, there were no detectable significant differences for A/Aichi/2/68 (p = 0.155) and A/Hong Kong/8/68 (p = 0.123) (<xref ref-type="fig" rid="pone.0199167.g004">Fig 4A</xref>). Catalase reversed the H3N2 virus-inactivating effects of OSCN<sup>-</sup> (<xref ref-type="fig" rid="pone.0199167.g004">Fig 4A</xref>). When OSCN<sup>-</sup> was replaced by I<sup>-</sup> as the LPO substrate in the cell-free system, it robustly enhanced viral inactivation that was significant (p&#x0003c;0.0005) for all four H3N2 IAVs (<xref ref-type="fig" rid="pone.0199167.g004">Fig 4A</xref>). The formation of OI<sup>-</sup> by LPO resulted in reduced titers of A/Wisconsin/67/2005 (4.21+/-0.25 log decrease, mean+/-S.E.M., n = 3), all other H3N2 strains were completely eliminated by the treatment (<xref ref-type="fig" rid="pone.0199167.g004">Fig 4A</xref>). The reversal of OI<sup>&#x02014;</sup>mediated H3N2 inactivation by catalase was highly significant (p&#x0003c;0.01) with all four strains tested (<xref ref-type="fig" rid="pone.0199167.g004">Fig 4A</xref>). We determined H3N2 IAV inactivation in the cell-free system and found it to be significantly (p = 0.029) more robust when I<sup>-</sup> was the LPO substrate used, compared to SCN<sup>-</sup> (<xref ref-type="fig" rid="pone.0199167.g004">Fig 4B</xref>).</p><fig id="pone.0199167.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0199167.g004</object-id><label>Fig 4</label><caption><title>Hypoiodite is more efficient in inactivating H3N2 influenza A viruses than hypothiocyanite in the cell-free system.</title><p>(A) The antiviral action of the cell-free H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system was tested against H3N2 influenza A strains: A/Texas/50/2012 (n = 3), A/Wisconsin/67/2005 (n = 2), A/Hong Kong/8/68 (n = 4) and A/Aichi/2/68 (n = 5). Viruses were incubated in the presence or absence of the components of the cell-free system as indicated for 1 hour and number of viable viruses was assessed by plate-forming unit assay using MDCK cells. Mean+/-S.E.M. One-way ANOVA, Dunn&#x02019;s multiple comparison test. (B) Virus inactivations of the H3N2 strains are compared according to the LPO substrates used. Mean+/-S.E.M., n = 2&#x02013;5. Mann-Whitney test. IAV, Influenza A virus; SCN<sup>-</sup>, thiocyanate; I<sup>-</sup>, iodide; LPO, lactoperoxidase; GO, glucose oxidase; MDCK, Madin-Darby canine kidney cells; PFU, plaque-forming unit.</p></caption><graphic xlink:href="pone.0199167.g004"/></fig><p>To assess potential association of hemagglutinin or neuraminidase types of IAVs with their susceptibility to the LPO-based system, we compared viral inactivation and substrate preference of all nine IAV strains tested. When IAVs tested so far were grouped according to their HA types (H1 and H3) or NA types (N1, N2), no significant differences were seen between them regarding OSCN<sup>&#x02014;</sup>or OI<sup>&#x02014;</sup>mediated viral inactivation (<xref ref-type="fig" rid="pone.0199167.g005">Fig 5A and 5B</xref>, left and middle panels). To better characterize the substrate preference of LPO-mediated viral inactivation, we calculated a &#x0201c;SCN<sup>-</sup> / I<sup>-</sup> substrate preference ratio&#x0201d; or &#x0201c;OSCN<sup>-</sup>/OI<sup>-</sup> susceptibility ratio&#x0201d; for each strain by dividing the extent of SCN<sup>&#x02014;</sup>fueled virus inactivation by the extent of the I<sup>&#x02014;</sup>mediated one. When these SCN<sup>-</sup>/I<sup>-</sup> substrate preference ratios of all nine IAV strains were grouped according to their HA type (irrespective of NA), they were significantly (p = 0.0159) higher with H1 compared to H3 (<xref ref-type="fig" rid="pone.0199167.g005">Fig 5A</xref>, right panel). When the substrate preference ratios were grouped according to the NA type (irrespective of HA), we found no significant (p = 0.111) difference (<xref ref-type="fig" rid="pone.0199167.g005">Fig 5B</xref>, right panel). In summary, H3N2 IAV strains are also susceptible to the antimicrobial actions of LPO and show a surprising preference for I<sup>-</sup> as the preferred substrate for inactivation that is associated with H1 and H3 hemagglutinin subtypes.</p><fig id="pone.0199167.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0199167.g005</object-id><label>Fig 5</label><caption><title>Hemagglutinin subtypes are associated with LPO substrate preference supporting IAV inactivation.</title><p>Susceptibilities of tested IAV strains to OSCN<sup>-</sup> and OI<sup>-</sup> in the cell-free system were compared according to their types of (A) hemagglutinin (H1, H3) and (B) neuraminidase (N1, N2). &#x0201c;SCN<sup>-</sup>/I<sup>-</sup> substrate preference ratios&#x0201d; were also calculated as described in the text for all nine IAV strains and compared among HA and NA types (upper and lower right panels). Ns, non-significant, *, p&#x0003c;0.05. SCN<sup>-</sup>, thiocyanate; OSCN<sup>-</sup>, hypothiocyanite; I<sup>-</sup>, iodide; OI<sup>-</sup>, hypoiodite; LPO, lactoperoxidase; GO, glucose oxidase; HA, hemagglutinin; NA, neuraminidase. The gray area highlights the only significant difference in the figure.</p></caption><graphic xlink:href="pone.0199167.g005"/></fig></sec><sec id="sec011"><title>The influenza B virus strain, B/Yamagata/16/1988, is more susceptible to hypothiocyanite than hypoiodite</title><p>IBV strains primarily infect humans, do not have established animal reservoirs and pose little risk of pandemic infection [<xref rid="pone.0199167.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0199167.ref031" ref-type="bibr">31</xref>]. IBV may cause seasonal influenza infections and co-circulate with IAV strains [<xref rid="pone.0199167.ref030" ref-type="bibr">30</xref>]. Importantly, IBV can dominate influenza seasons and is typically more resistant to antivirals than IAVs [<xref rid="pone.0199167.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0199167.ref032" ref-type="bibr">32</xref>]. We investigated whether LPO present in our cell-free system can inactivate the influenza B strain, B/Yamagata/16/1988, a prototype strain of the Yamagata lineage of IBV strains [<xref rid="pone.0199167.ref033" ref-type="bibr">33</xref>]. As shown in <xref ref-type="fig" rid="pone.0199167.g006">Fig 6A</xref>, OSCN<sup>-</sup> led to complete, highly significant (p&#x0003c;0.001) inactivation of the viral dose used. Using I<sup>-</sup> as the LPO substrate, viral inactivation of IBV was significant (p = 0.021), but was reduced to a 1.6+/-0.62 log decrease (n = 5) in viral titers compared to 7.2+/-0.27 log drop (n = 5) in viral titers following OSCN<sup>-</sup> production (<xref ref-type="fig" rid="pone.0199167.g006">Fig 6A</xref>). As in the case of IAV strains, both, OSCN<sup>&#x02014;</sup>and OI<sup>&#x02014;</sup>mediated inactivation of this IBV strain was completely inhibited by catalase, as well (<xref ref-type="fig" rid="pone.0199167.g006">Fig 6A</xref>). Since the used dose of I<sup>-</sup> sustained only minor inactivation of the tested IBV strain, we increased the I<sup>-</sup> concentration to 40 mM to explore the potential improvement of the antiviral action of LPO. Unexpectedly, we did not observe improved inactivation of the B/Yamagata/16/1988 strain by up to 100-fold higher I<sup>-</sup> doses (<xref ref-type="fig" rid="pone.0199167.g006">Fig 6B</xref>). Thus, the tested IBV strain showed a preference for SCN<sup>-</sup> as the LPO substrate for inactivation.</p><fig id="pone.0199167.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0199167.g006</object-id><label>Fig 6</label><caption><title>LPO substrate preference of Influenza B virus inactivation is strain-dependent.</title><p>(A) The antiviral action of the cell-free H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system was tested against influenza B strains: B/Yamagata/16/1988, B/Great Lakes/1739/1954 and B/New York/1056/2003. Viruses were incubated in the presence or absence of the components of the cell-free system as indicated for 1 hour and viral inactivation was assessed by plate-forming unit assay using MDCK cells. Mean+/-S.E.M., n = 5. One-way ANOVA, Dunn&#x02019;s multiple comparison test. (B) B/Yamagata/16/1988 Virus inactivation was measured at increasing I<sup>-</sup> concentrations (0.4&#x02013;40 mM) in the cell-free system by the PFU assay. Mean+/-S.E.M., n = 5. One-way ANOVA, Dunn&#x02019;s multiple comparison test. (C) The extents of IBV inactivation by OSCN<sup>-</sup> and OI<sup>-</sup> of the three strains tested were compared. Mean+/-S.E.M., Mann-Whitney test. Ns, not significant; *, p&#x0003c;0.05; **, p&#x0003c;0.01; ***, p&#x0003c;0.001. SCN<sup>-</sup>, thiocyanate; OSCN<sup>-</sup>, hypothiocyanite; I<sup>-</sup>, iodide; OI<sup>-</sup>, hypoiodite; LPO, lactoperoxidase; GO, glucose oxidase; MDCK, Madin-Darby canine kidney cells; PFU, plaque-forming unit; IBV, Influenza B virus.</p></caption><graphic xlink:href="pone.0199167.g006"/></fig></sec><sec id="sec012"><title>The substrate preference of influenza B strains for LPO-mediated inactivation is strain-dependent</title><p>To test whether the observed, marked difference in susceptibility to OSCN<sup>-</sup> versus OI<sup>-</sup> of the B/Yamagata/16/1988 strain (<xref ref-type="fig" rid="pone.0199167.g006">Fig 6A and 6B</xref>) is a unique feature of this strain or is generally true for all IBV strains, we tested two additional IBV strains. The B/Great Lakes/1739/1954 strain that also belongs to the Yamagata lineage [<xref rid="pone.0199167.ref034" ref-type="bibr">34</xref>] was efficiently inactivated (n = 5) by both, OSCN<sup>-</sup> (6.00+/-0.98 log decrease) and OI<sup>-</sup> (4.34+/-1.13 log decrease), with a slight preference to OSCN<sup>-</sup> (<xref ref-type="fig" rid="pone.0199167.g006">Fig 6A</xref>). The B/New York/1056/2003 IBV strain belongs to the Victoria lineage and has been isolated from a pharyngeal swab from a human with unspecified respiratory disease (BEI Resources). This Victoria lineage strain was equally inactivated by OSCN<sup>-</sup> (3.23+/-1.00 log decrease) and OI<sup>-</sup> (3.23+/-0.75 log decrease, n = 3) (<xref ref-type="fig" rid="pone.0199167.g006">Fig 6A</xref>). LPO-mediated inactivation of all three IBV strains was entirely blocked by catalase (<xref ref-type="fig" rid="pone.0199167.g006">Fig 6A</xref>). Although there is a trend towards OSCN<sup>-</sup>, data shown in <xref ref-type="fig" rid="pone.0199167.g006">Fig 6C</xref> did not find an overall significant difference between OSCN<sup>&#x02014;</sup>fueled and OI<sup>&#x02014;</sup>mediated inactivation of IBV strains.</p></sec><sec id="sec013"><title>Influenza B viruses have a significantly higher OSCN<sup>-</sup>/OI<sup>-</sup> susceptibility ratio than influenza A strains</title><p>To explore whether there are differences in the previous readouts between IAV and IBV strains, we compared susceptibilities to OSCN<sup>-</sup> and OI<sup>-</sup>, as well as, their ratio called &#x0201c;OSCN<sup>-</sup>/OI<sup>-</sup> susceptibility ratio&#x0201d; between the IAV and IBV strains analyzed. As <xref ref-type="fig" rid="pone.0199167.g007">Fig 7</xref> shows, there was no significant difference between the two viral species in their susceptibilities to the virucidal agents. However, we observed a significant difference (p = 0.0182) in their susceptibility ratios as shown in <xref ref-type="fig" rid="pone.0199167.g007">Fig 7</xref> (right panel). All IAV strains had very low ratios (0.73+/-0.13, mean+/-S.E.M., n = 9) while IBV strains had much higher values (4.00+/-2.35, mean+/-S.E.M., n = 3) (<xref ref-type="fig" rid="pone.0199167.g007">Fig 7</xref>). Thus, IBV strains tend to be more sensitive to OSCN<sup>-</sup> whereas IAV strains are equally sensitive to both LPO substrates or more susceptible to OI<sup>-</sup>.</p><fig id="pone.0199167.g007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0199167.g007</object-id><label>Fig 7</label><caption><p><bold>Comparison of influenza A and B strains for their susceptibilities to the virucidal effects of LPO.</bold> The nine IAV and three IBV influenza strains tested were compared regarding their susceptibilities to OSCN<sup>-</sup> (left panel), to OI<sup>-</sup> (middle panel) or their LPO substrate preference ratios (right panel) in the cell-free system. This figure does not show new experimental data but presents new analysis of experimental results obtained in Figs <xref ref-type="fig" rid="pone.0199167.g002">2</xref>&#x02013;<xref ref-type="fig" rid="pone.0199167.g006">6</xref>. The gray area highlights the only significant difference in the figure. Mean+/-S.E.M., Mann-Whitney test. Ns, not significant; *, p&#x0003c;0.05. OSCN<sup>-</sup>, hypothiocyanite; OI<sup>-</sup>, hypoiodite; IAV, influenza A virus; IBV, influenza B virus.</p></caption><graphic xlink:href="pone.0199167.g007"/></fig></sec><sec id="sec014"><title>Substrate specificity map of influenza inactivation by LPO</title><p>To summarize our results after surveying 12 different influenza strains for their susceptibilities and LPO substrate preferences in the H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system, we plotted our data as a &#x0201c;substrate preference or susceptibility map&#x0201d; shown in <xref ref-type="fig" rid="pone.0199167.g008">Fig 8</xref>. The X-axis represents the extent of viral inactivation that is associated with OSCN<sup>-</sup>, while the Y-axis represents the extent of viral inactivation by OI<sup>-</sup>. The higher the number, the more susceptible a particular virus strain is to the indicated, LPO-generated antiviral agent (<xref ref-type="fig" rid="pone.0199167.g008">Fig 8</xref>). The indicated diagonal crossing the map from the lower left corner to the upper right corner indicates no substrate preference (<xref ref-type="fig" rid="pone.0199167.g008">Fig 8</xref>). The H1N2 influenza strain tested localizes to the upper right corner indicating high susceptibility to the LPO-based antimicrobial system with no considerable preference for the LPO substrate (<xref ref-type="fig" rid="pone.0199167.g008">Fig 8</xref>). All H1N1 strains appear on the diagonal showing no preference for the LPO substrate. While the A/Brisbane/59/2007 strain can be found in the lower left corner, the A/California/04/2009, A/Mississippi/3/2001, and A/Turkey/Kansas/4880/1980 strains are, however, all located in the upper right corner, close to the H1N2 strain, representing widely distinct susceptibilities of the tested H1N1 viruses towards the H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system. All four H3N2 influenza A strains showed a clear and noteworthy preference for I<sup>-</sup> as the LPO substrate for their inactivation in the cell-free system and were grouped together into an &#x0201c;H3N2 cluster&#x0201d; (<xref ref-type="fig" rid="pone.0199167.g008">Fig 8</xref>). The first IBV strain tested (B/Yamagata/16/1988) mapped into the lower right corner indicating its highly susceptible nature to OSCN<sup>-</sup> but almost resistance towards OI<sup>-</sup> (<xref ref-type="fig" rid="pone.0199167.g008">Fig 8</xref>). Two further IBV strains, however, failed to confirm this trend and localized to the vicinity of the center of the graph. Overall, our work represents an unexpected complexity of influenza virus inactivation by the H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system.</p><fig id="pone.0199167.g008" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0199167.g008</object-id><label>Fig 8</label><caption><title>LPO substrate specificity and susceptibility map of influenza strains.</title><p>Susceptibilities of all twelve influenza strains tested in this study against OSCN<sup>-</sup> or OI<sup>-</sup> in the cell-free system are plotted. Names, species, serotypes or subtypes of the viral strains are indicated. Susceptibility is defined as the decrease in viral doses (log<sub>10</sub>PFU/ml) in the cell-free system following catalase treatment&#x02014;see text for further details. The X axis shows susceptibility against OSCN<sup>-</sup> while the Y axis shows susceptibility towards OI<sup>-</sup>. Mean+/-S.E.M. for both, X and Y axes, n = 2&#x02013;5. The indicated diagonal crossing on the map from the lower left corner to the upper right corner indicates no substrate preference, irrespective of susceptibility. The dotted line named as the &#x0201c;H3N2 cluster&#x0201d; indicates that all four H3N2 strains group close to each other. The quadrant circles indicate viral inactivations of different sizes (2.5, 5.0 and 7.5 logs). OSCN<sup>-</sup>, hypothiocyanite; OI<sup>-</sup>, hypoiodite; LPO, lactoperoxidase; PFU, plaque-forming unit; IAV, Influenza A virus; IBV, Influenza B virus.</p></caption><graphic xlink:href="pone.0199167.g008"/></fig></sec></sec><sec sec-type="conclusions" id="sec015"><title>Discussion</title><p>Seasonal and pandemic infections by influenza viruses represent a major threat. Seasonal influenza viruses infect 5&#x02013;15% of the human population annually, resulting in more than half a million deaths worldwide [<xref rid="pone.0199167.ref035" ref-type="bibr">35</xref>]. Strain complexity, virus drift, and viral reassortment make it difficult to develop vaccines providing protection against a wide range of influenza strains. Current trivalent vaccines include one H1N1, one H3N2 IAV strain and one IBV strain of either the Yamagata or Victoria lineages [<xref rid="pone.0199167.ref035" ref-type="bibr">35</xref>]. Quadrivalent vaccines include two influenza B strains, one Yamagata and one Victoria strain, in addition to the two IAV strains [<xref rid="pone.0199167.ref035" ref-type="bibr">35</xref>]. The efficacy of the annual influenza vaccine varies widely from 10&#x02013;60% [<xref rid="pone.0199167.ref036" ref-type="bibr">36</xref>], and the vaccine does not provide universal influenza virus protection [<xref rid="pone.0199167.ref036" ref-type="bibr">36</xref>]. Currently, all antivirals face the problem of increasing drug resistance [<xref rid="pone.0199167.ref037" ref-type="bibr">37</xref>]. Therefore, there is an urgent need to find novel mechanisms by which influenza can be fought, preferably in a strain-independent fashion.</p><p>The H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system represents an oxidative, fast-reacting mechanism of the respiratory innate immune system that is capable of killing or inactivating a wide range of pathogens. Our results reported here are one of the first ones to document its efficacy against influenza virus. Our prior results established that the H<sub>2</sub>O<sub>2</sub>/LPO/SCN<sup>-</sup> system assembled in <italic>in vitro</italic> cultures of differentiated, human and rat, tracheobronchial epithelial cells inactivates the A/Swine/Illinois/02860/2009 influenza A strain [<xref rid="pone.0199167.ref009" ref-type="bibr">9</xref>]. Here we confirmed that H<sub>2</sub>O<sub>2</sub>/LPO/SCN<sup>-</sup> system behaves in a very similar fashion and inactivates the same H1N2 strain under cell-free experimental conditions. This cell-free system provides us with an important tool to address the specificity and the mechanism of action of the LPO-based system against influenza viruses. It is important to emphasize that influenza viruses are inactivated by the H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system in both the cell-free and airway epithelial model [<xref rid="pone.0199167.ref009" ref-type="bibr">9</xref>] in less than 60 minutes. Very few, if any, mechanism of the innate immune system reacts so fast and efficiently.</p><p>In the current work we expanded our observation made on the IAV H1N2 strain to other influenza strains. Our central focus has been to address the question of whether SCN<sup>-</sup> or I<sup>-</sup> serves as a better substrate for the anti-influenza action of LPO. We revealed a LPO substrate preference of influenza inactivation that appears more complex than expected. Based on the current survey of influenza strains we conclude that H3N2 IAV strains are inactivated by OI<sup>-</sup> more effectively than by OSCN<sup>-</sup>. This is presented as an &#x0201c;H3N2 cluster&#x0201d; on LPO&#x02019;s substrate preference map (<xref ref-type="fig" rid="pone.0199167.g008">Fig 8</xref>). We did not find this bias towards I<sup>-</sup> in case of the other IAVs (H1N1 and H1N2) that were inactivated by the LPO substrates. The potential explanation for this is unclear at the moment but redox-sensitive disulfide bonds may be different among HA or NA subtypes that could help explain this observation [<xref rid="pone.0199167.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0199167.ref039" ref-type="bibr">39</xref>]. Differences in OI<sup>&#x02014;</sup>or OSCN<sup>&#x02014;</sup>mediated oxidative modifications of these bonds could lead to altered virion disassembly or inhibition of viral entry into host cells [<xref rid="pone.0199167.ref039" ref-type="bibr">39</xref>, <xref rid="pone.0199167.ref040" ref-type="bibr">40</xref>]. Oxidative stress has been shown to inactivate influenza viruses [<xref rid="pone.0199167.ref041" ref-type="bibr">41</xref>]. Oxidative damage of the lipid components of the viral envelope or the nucleoprotein could be also the results of the antimicrobial action of LPO [<xref rid="pone.0199167.ref041" ref-type="bibr">41</xref>]. Differences in susceptibilities of influenza viruses to polyphenols were linked to viral envelope glycoproteins [<xref rid="pone.0199167.ref042" ref-type="bibr">42</xref>]. OI<sup>-</sup> has a higher oxidative strength than OSCN<sup>-</sup> [<xref rid="pone.0199167.ref043" ref-type="bibr">43</xref>]. While the main potential targets of OSCN<sup>-</sup>/HOSCN are certain SH groups, OI<sup>-</sup>/HOI can target SH groups, NAD(P)H, reduced pyridine nucleotides, thioether groups and NH2 groups [<xref rid="pone.0199167.ref043" ref-type="bibr">43</xref>]. These molecular differences could form the basis for the observed inactivation patterns of influenza viruses in our study. The virucidal effect of OSCN<sup>-</sup> and OI<sup>-</sup> may be due to their ability to either interact with viral HA or NA directly and interfere with viral cell entry or to cross the outer layer of the viral envelop before oxidizing critical viral elements inside the virion. We know that beneath the lipid membrane of the influenza virus, a viral protein called M1 matrix protein is expressed and may be reacting with OSCN<sup>-</sup> or OI<sup>-</sup> and interfere with viral infectivity [<xref rid="pone.0199167.ref044" ref-type="bibr">44</xref>]. Other viral proteins that are cysteine-rich may be the targets of these antiviral agents. In bacteria, for example, the reported bacterial targets of OSCN<sup>-</sup> are critical cysteine residues found in glycolytic enzymes, such as glyceraldehyde triphosphate dehydrogenase, hexokinase, glycose-6-phosphate dehydrogenase, and aldolase leading to the hypothesis that OSCN<sup>-</sup> effect on bacterial growth is glycolysis-mediated [<xref rid="pone.0199167.ref045" ref-type="bibr">45</xref>]. Glucose transport and respiration may also be the target of OSCN<sup>-</sup> and OI<sup>-</sup>. It has been reported to inhibit the activity of urease, which is critical to the ability of H. pylori to alkalinize gastric juice and colonize the stomach [<xref rid="pone.0199167.ref046" ref-type="bibr">46</xref>].</p><p>IBVs can cause symptoms similar to IAVs in humans, and are responsible for a large proportion of seasonal influenza infections [<xref rid="pone.0199167.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0199167.ref032" ref-type="bibr">32</xref>]. Far less is known regarding the viral and host determinants of IBV disease pathogenicity [<xref rid="pone.0199167.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0199167.ref032" ref-type="bibr">32</xref>]. The immune response against IBV is affected by yearly trivalent or quadrivalent vaccines and typically is weaker in humans than that against IAVs [<xref rid="pone.0199167.ref030" ref-type="bibr">30</xref>]. NA inhibitors that work well against most strains of IAV are typically less effective for IBVs [<xref rid="pone.0199167.ref030" ref-type="bibr">30</xref>]. Therefore, novel approaches are needed to confront IBV. Our results show that the B/Yamagata/16/1988 strain is sensitive against the H<sub>2</sub>O<sub>2</sub>/LPO/SCN<sup>-</sup> system but remains more resistant against the H<sub>2</sub>O<sub>2</sub>/LPO/I<sup>-</sup> system. After testing two other IBV strains, this pattern failed to be confirmed suggesting that it could be strain-specific. Testing a larger number of IBV strains is needed for a firmer conclusion. Nevertheless, our findings are the first to show that the H<sub>2</sub>O<sub>2</sub>/LPO/SCN<sup>-</sup> antimicrobial system efficiently inactivates IBV strains, as well.</p><p>Given the wealth of historical data showing that these LPO-generated products have antimicrobial effects, they could be used for either therapeutic or prophylactic supplementation before infection or drugs, in combination with current anti-influenza therapies to enhance viral elimination and diminish inflammation. SCN<sup>-</sup> is present in the diet and no serious adverse effects of SCN<sup>-</sup> in humans have been reported at physiological concentrations (reviewed in [<xref rid="pone.0199167.ref047" ref-type="bibr">47</xref>]). Iodide intake has already been proposed to improve viral clearance but has several hurdles. While lower dose of iodide intake is safe and associated with normal thyroid function, recent works have proven that alterations in thyroid function are associated with high iodide supplementation in maternal rats and their offspring [<xref rid="pone.0199167.ref048" ref-type="bibr">48</xref>]. Other findings show that treatment <italic>in vivo</italic> with an excess of iodide can induce the blockade of thyroid hormone biosynthesis [<xref rid="pone.0199167.ref049" ref-type="bibr">49</xref>] and excess of iodide could induce mononuclear infiltration in salivary gland as recently indicated in a Swiss albino mouse model [<xref rid="pone.0199167.ref050" ref-type="bibr">50</xref>] These results question whether iodide supplementation would work to boost anti-influenza defenses.</p><p>In summary, the findings presented here shows that the H<sub>2</sub>O<sub>2</sub>/LPO/(SCN<sup>-</sup>/I<sup>-</sup>) system robustly inactivates a wide range of influenza viruses that are the major circulating serotypes and species causing epidemics and are also components of the annual influenza vaccine. These results are very encouraging considering the likely contribution of this mechanism to <italic>in vivo</italic> influenza clearance and its potential as a target for pharmaceutical intervention.</p></sec><sec sec-type="supplementary-material" id="sec016"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0199167.s001"><label>S1 Data</label><caption><title>Plaque forming unit results.</title><p>The original data of the plaque forming unit assays using MDCK cells of the virus strains tested in this work are shown for each experiment organized according to the figures.</p><p>(XLSX)</p></caption><media xlink:href="pone.0199167.s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors would like to thank Jackelyn Crabtree working in the Tripp laboratory for her help with ordering and initial propagation of some of the influenza strains.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>Duox1</term><def><p>Dual oxidase 1</p></def></def-item><def-item><term>GO</term><def><p>glucose oxidase</p></def></def-item><def-item><term>HA</term><def><p>hemagglutinin</p></def></def-item><def-item><term>OI<sup>-</sup></term><def><p>hypoiodite</p></def></def-item><def-item><term>OSCN<sup>-</sup></term><def><p>hypothiocyanite</p></def></def-item><def-item><term>IAV</term><def><p>influenza A virus</p></def></def-item><def-item><term>IBV</term><def><p>influenza B virus</p></def></def-item><def-item><term>I<sup>-</sup></term><def><p>iodide</p></def></def-item><def-item><term>LPO</term><def><p>lactoperoxidase</p></def></def-item><def-item><term>MDCK</term><def><p>Madin-Darby canine kidney cells</p></def></def-item><def-item><term>NA</term><def><p>neuraminidase</p></def></def-item><def-item><term>SCN<sup>-</sup></term><def><p>thiocyanate</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0199167.ref001"><label>1</label><mixed-citation publication-type="journal"><article-title>Review of the 2014&#x02013;2015 influenza season in the northern hemisphere</article-title>. <source>Wkly Epidemiol Rec</source>. <year>2015</year>;<volume>90</volume>(<issue>23</issue>):<fpage>281</fpage>&#x02013;<lpage>96</lpage>. <?supplied-pmid 26050269?><pub-id pub-id-type="pmid">26050269</pub-id></mixed-citation></ref><ref id="pone.0199167.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Hsieh</surname><given-names>CS</given-names></name>, <name><surname>Lee</surname><given-names>HM</given-names></name>, <name><surname>Lio</surname><given-names>CW</given-names></name>. <article-title>Selection of regulatory T cells in the thymus</article-title>. <source>Nat Rev Immunol</source>. <year>2012</year>;<volume>12</volume>:<fpage>157</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1038/nri3155</pub-id>
<?supplied-pmid 22322317?><pub-id pub-id-type="pmid">22322317</pub-id></mixed-citation></ref><ref id="pone.0199167.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Lowen</surname><given-names>AC</given-names></name>. <article-title>Constraints, Drivers, and Implications of Influenza A Virus Reassortment</article-title>. <source>Annu Rev Virol</source>. <year>2017</year>;<volume>4</volume>(<issue>1</issue>):<fpage>105</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-virology-101416-041726</pub-id>
<?supplied-pmid 28548881?><pub-id pub-id-type="pmid">28548881</pub-id></mixed-citation></ref><ref id="pone.0199167.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Pinsent</surname><given-names>A</given-names></name>, <name><surname>Fraser</surname><given-names>C</given-names></name>, <name><surname>Ferguson</surname><given-names>NM</given-names></name>, <name><surname>Riley</surname><given-names>S</given-names></name>. <article-title>A systematic review of reported reassortant viral lineages of influenza A</article-title>. <source>BMC Infect Dis</source>. <year>2016</year>;<volume>16</volume>:<fpage>3</fpage>
<pub-id pub-id-type="doi">10.1186/s12879-015-1298-9</pub-id>
<?supplied-pmid 26732146?><pub-id pub-id-type="pmid">26732146</pub-id></mixed-citation></ref><ref id="pone.0199167.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Spanakis</surname><given-names>N</given-names></name>, <name><surname>Pitiriga</surname><given-names>V</given-names></name>, <name><surname>Gennimata</surname><given-names>V</given-names></name>, <name><surname>Tsakris</surname><given-names>A</given-names></name>. <article-title>A review of neuraminidase inhibitor susceptibility in influenza strains</article-title>. <source>Expert Rev Anti Infect Ther</source>. <year>2014</year>;<volume>12</volume>(<issue>11</issue>):<fpage>1325</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1586/14787210.2014.966083</pub-id>
<?supplied-pmid 25301229?><pub-id pub-id-type="pmid">25301229</pub-id></mixed-citation></ref><ref id="pone.0199167.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Londino</surname><given-names>JD</given-names></name>, <name><surname>Lazrak</surname><given-names>A</given-names></name>, <name><surname>Collawn</surname><given-names>JF</given-names></name>, <name><surname>Bebok</surname><given-names>Z</given-names></name>, <name><surname>Harrod</surname><given-names>KS</given-names></name>, <name><surname>Matalon</surname><given-names>S</given-names></name>. <article-title>Influenza virus infection alters ion channel function of airway and alveolar cells: mechanisms and physiological sequelae</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <year>2017</year>;<volume>313</volume>(<issue>5</issue>):<fpage>L845</fpage>&#x02013;<lpage>L58</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00244.2017</pub-id>
<?supplied-pmid 28775098?><pub-id pub-id-type="pmid">28775098</pub-id></mixed-citation></ref><ref id="pone.0199167.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Herold</surname><given-names>S</given-names></name>, <name><surname>Becker</surname><given-names>C</given-names></name>, <name><surname>Ridge</surname><given-names>KM</given-names></name>, <name><surname>Budinger</surname><given-names>GR</given-names></name>. <article-title>Influenza virus-induced lung injury: pathogenesis and implications for treatment</article-title>. <source>Eur Respir J</source>. <year>2015</year>;<volume>45</volume>(<issue>5</issue>):<fpage>1463</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00186214</pub-id>
<?supplied-pmid 25792631?><pub-id pub-id-type="pmid">25792631</pub-id></mixed-citation></ref><ref id="pone.0199167.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Geiszt</surname><given-names>M</given-names></name>, <name><surname>Witta</surname><given-names>J</given-names></name>, <name><surname>Baffi</surname><given-names>J</given-names></name>, <name><surname>Lekstrom</surname><given-names>K</given-names></name>, <name><surname>Leto</surname><given-names>TL</given-names></name>. <article-title>Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense</article-title>. <source>FASEB J</source>. <year>2003</year>;<volume>17</volume>(<issue>11</issue>):<fpage>1502</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1096/fj.02-1104fje</pub-id>
<?supplied-pmid 12824283?><pub-id pub-id-type="pmid">12824283</pub-id></mixed-citation></ref><ref id="pone.0199167.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Gingerich</surname><given-names>A</given-names></name>, <name><surname>Pang</surname><given-names>L</given-names></name>, <name><surname>Hanson</surname><given-names>J</given-names></name>, <name><surname>Dlugolenski</surname><given-names>D</given-names></name>, <name><surname>Streich</surname><given-names>R</given-names></name>, <name><surname>Lafontaine</surname><given-names>ER</given-names></name>, <etal>et al</etal>
<article-title>Hypothiocyanite produced by human and rat respiratory epithelial cells inactivates extracellular H1N2 influenza A virus</article-title>. <source>Inflamm Res</source>. <year>2016</year>;<volume>65</volume>(<issue>1</issue>):<fpage>71</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1007/s00011-015-0892-z</pub-id>
<?supplied-pmid 26608498?><pub-id pub-id-type="pmid">26608498</pub-id></mixed-citation></ref><ref id="pone.0199167.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Rada</surname><given-names>B</given-names></name>, <name><surname>Leto</surname><given-names>TL</given-names></name>. <article-title>Oxidative innate immune defenses by Nox/Duox family NADPH oxidases</article-title>. <source>Contrib Microbiol</source>. <year>2008</year>;<volume>15</volume>:<fpage>164</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1159/000136357</pub-id>
<?supplied-pmid 18511861?><pub-id pub-id-type="pmid">18511861</pub-id></mixed-citation></ref><ref id="pone.0199167.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Rada</surname><given-names>B</given-names></name>, <name><surname>Leto</surname><given-names>TL</given-names></name>. <article-title>Redox warfare between airway epithelial cells and Pseudomonas: dual oxidase versus pyocyanin</article-title>. <source>Immunol Res</source>. <year>2009</year>;<volume>43</volume>(<issue>1&#x02013;3</issue>):<fpage>198</fpage>&#x02013;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-008-8071-8</pub-id>
<?supplied-pmid 18979077?><pub-id pub-id-type="pmid">18979077</pub-id></mixed-citation></ref><ref id="pone.0199167.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Gerson</surname><given-names>C</given-names></name>, <name><surname>Sabater</surname><given-names>J</given-names></name>, <name><surname>Scuri</surname><given-names>M</given-names></name>, <name><surname>Torbati</surname><given-names>A</given-names></name>, <name><surname>Coffey</surname><given-names>R</given-names></name>, <name><surname>Abraham</surname><given-names>JW</given-names></name>, <etal>et al</etal>
<article-title>The lactoperoxidase system functions in bacterial clearance of airways</article-title>. <source>Am J Respir Cell Mol Biol</source>. <year>2000</year>;<volume>22</volume>(<issue>6</issue>):<fpage>665</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1165/ajrcmb.22.6.3980</pub-id>
<?supplied-pmid 10837362?><pub-id pub-id-type="pmid">10837362</pub-id></mixed-citation></ref><ref id="pone.0199167.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Cegolon</surname><given-names>L</given-names></name>, <name><surname>Salata</surname><given-names>C</given-names></name>, <name><surname>Piccoli</surname><given-names>E</given-names></name>, <name><surname>Juarez</surname><given-names>V</given-names></name>, <name><surname>Palu</surname><given-names>G</given-names></name>, <name><surname>Mastrangelo</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>In vitro antiviral activity of hypothiocyanite against A/H1N1/2009 pandemic influenza virus</article-title>. <source>Int J Hyg Environ Health</source>. <year>2014</year>;<volume>217</volume>(<issue>1</issue>):<fpage>17</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijheh.2013.03.001</pub-id>
<?supplied-pmid 23540488?><pub-id pub-id-type="pmid">23540488</pub-id></mixed-citation></ref><ref id="pone.0199167.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Sharma</surname><given-names>S</given-names></name>, <name><surname>Singh</surname><given-names>AK</given-names></name>, <name><surname>Kaushik</surname><given-names>S</given-names></name>, <name><surname>Sinha</surname><given-names>M</given-names></name>, <name><surname>Singh</surname><given-names>RP</given-names></name>, <name><surname>Sharma</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Lactoperoxidase: structural insights into the function,ligand binding and inhibition</article-title>. <source>Int J Biochem Mol Biol</source>. <year>2013</year>;<volume>4</volume>(<issue>3</issue>):<fpage>108</fpage>&#x02013;<lpage>28</lpage>. <?supplied-pmid 24049667?><pub-id pub-id-type="pmid">24049667</pub-id></mixed-citation></ref><ref id="pone.0199167.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Ahariz</surname><given-names>M</given-names></name>, <name><surname>Courtois</surname><given-names>P</given-names></name>. <article-title>Candida albicans susceptibility to lactoperoxidase-generated hypoiodite</article-title>. <source>Clin Cosmet Investig Dent</source>. <year>2010</year>;<volume>2</volume>:<fpage>69</fpage>&#x02013;<lpage>78</lpage>. <?supplied-pmid 23662084?><pub-id pub-id-type="pmid">23662084</pub-id></mixed-citation></ref><ref id="pone.0199167.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Schlorke</surname><given-names>D</given-names></name>, <name><surname>Atosuo</surname><given-names>J</given-names></name>, <name><surname>Flemmig</surname><given-names>J</given-names></name>, <name><surname>Lilius</surname><given-names>EM</given-names></name>, <name><surname>Arnhold</surname><given-names>J</given-names></name>. <article-title>Impact of cyanogen iodide in killing of Escherichia coli by the lactoperoxidase-hydrogen peroxide-(pseudo)halide system</article-title>. <source>Free Radic Res</source>. <year>2016</year>;<volume>50</volume>(<issue>12</issue>):<fpage>1287</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1080/10715762.2016.1235789</pub-id>
<?supplied-pmid 27629563?><pub-id pub-id-type="pmid">27629563</pub-id></mixed-citation></ref><ref id="pone.0199167.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Dlugolenski</surname><given-names>D</given-names></name>, <name><surname>Jones</surname><given-names>L</given-names></name>, <name><surname>Howerth</surname><given-names>E</given-names></name>, <name><surname>Wentworth</surname><given-names>D</given-names></name>, <name><surname>Tompkins</surname><given-names>SM</given-names></name>, <name><surname>Tripp</surname><given-names>RA</given-names></name>. <article-title>Swine Influenza Virus PA and Neuraminidase Gene Reassortment into Human H1N1 Influenza Virus Is Associated with an Altered Pathogenic Phenotype Linked to Increased MIP-2 Expression</article-title>. <source>J Virol</source>. <year>2015</year>;<volume>89</volume>(<issue>10</issue>):<fpage>5651</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00087-15</pub-id>
<?supplied-pmid 25762737?><pub-id pub-id-type="pmid">25762737</pub-id></mixed-citation></ref><ref id="pone.0199167.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Wijkstrom-Frei</surname><given-names>C</given-names></name>, <name><surname>El-Chemaly</surname><given-names>S</given-names></name>, <name><surname>Ali-Rachedi</surname><given-names>R</given-names></name>, <name><surname>Gerson</surname><given-names>C</given-names></name>, <name><surname>Cobas</surname><given-names>MA</given-names></name>, <name><surname>Forteza</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Lactoperoxidase and human airway host defense</article-title>. <source>Am J Respir Cell Mol Biol</source>. <year>2003</year>;<volume>29</volume>(<issue>2</issue>):<fpage>206</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2002-0152OC</pub-id>
<?supplied-pmid 12626341?><pub-id pub-id-type="pmid">12626341</pub-id></mixed-citation></ref><ref id="pone.0199167.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Conner</surname><given-names>GE</given-names></name>, <name><surname>Salathe</surname><given-names>M</given-names></name>, <name><surname>Forteza</surname><given-names>R</given-names></name>. <article-title>Lactoperoxidase and hydrogen peroxide metabolism in the airway</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2002</year>;<volume>166</volume>(<issue>12</issue> Pt 2):<fpage>S57</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">12471090</pub-id></mixed-citation></ref><ref id="pone.0199167.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Rada</surname><given-names>B</given-names></name>, <name><surname>Lekstrom</surname><given-names>K</given-names></name>, <name><surname>Damian</surname><given-names>S</given-names></name>, <name><surname>Dupuy</surname><given-names>C</given-names></name>, <name><surname>Leto</surname><given-names>TL</given-names></name>. <article-title>The Pseudomonas toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells</article-title>. <source>J Immunol</source>. <year>2008</year>;<volume>181</volume>(<issue>7</issue>):<fpage>4883</fpage>&#x02013;<lpage>93</lpage>. <?supplied-pmid 18802092?><pub-id pub-id-type="pmid">18802092</pub-id></mixed-citation></ref><ref id="pone.0199167.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Rada</surname><given-names>B</given-names></name>, <name><surname>Leto</surname><given-names>TL</given-names></name>. <article-title>Characterization of hydrogen peroxide production by Duox in bronchial epithelial cells exposed to Pseudomonas aeruginosa</article-title>. <source>FEBS Lett</source>. <year>2010</year>;<volume>584</volume>(<issue>5</issue>):<fpage>917</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2010.01.025</pub-id>
<?supplied-pmid 20085766?><pub-id pub-id-type="pmid">20085766</pub-id></mixed-citation></ref><ref id="pone.0199167.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Derscheid</surname><given-names>RJ</given-names></name>, <name><surname>van Geelen</surname><given-names>A</given-names></name>, <name><surname>Berkebile</surname><given-names>AR</given-names></name>, <name><surname>Gallup</surname><given-names>JM</given-names></name>, <name><surname>Hostetter</surname><given-names>SJ</given-names></name>, <name><surname>Banfi</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Increased concentration of iodide in airway secretions is associated with reduced respiratory syncytial virus disease severity</article-title>. <source>Am J Respir Cell Mol Biol</source>. <year>2014</year>;<volume>50</volume>(<issue>2</issue>):<fpage>389</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2012-0529OC</pub-id>
<?supplied-pmid 24053146?><pub-id pub-id-type="pmid">24053146</pub-id></mixed-citation></ref><ref id="pone.0199167.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Retamal</surname><given-names>M</given-names></name>, <name><surname>Abed</surname><given-names>Y</given-names></name>, <name><surname>Corbeil</surname><given-names>J</given-names></name>, <name><surname>Boivin</surname><given-names>G</given-names></name>. <article-title>Epitope mapping of the 2009 pandemic and the A/Brisbane/59/2007 seasonal (H1N1) influenza virus haemagglutinins using mAbs and escape mutants</article-title>. <source>J Gen Virol</source>. <year>2014</year>;<volume>95</volume>(<issue>Pt 11</issue>):<fpage>2377</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.067819-0</pub-id>
<?supplied-pmid 25078301?><pub-id pub-id-type="pmid">25078301</pub-id></mixed-citation></ref><ref id="pone.0199167.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Clark</surname><given-names>AM</given-names></name>, <name><surname>DeDiego</surname><given-names>ML</given-names></name>, <name><surname>Anderson</surname><given-names>CS</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Yang</surname><given-names>H</given-names></name>, <name><surname>Nogales</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Antigenicity of the 2015&#x02013;2016 seasonal H1N1 human influenza virus HA and NA proteins</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>11</issue>):<fpage>e0188267</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0188267</pub-id>
<?supplied-pmid 29145498?><pub-id pub-id-type="pmid">29145498</pub-id></mixed-citation></ref><ref id="pone.0199167.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Kilbourne</surname><given-names>ED</given-names></name>, <name><surname>Taylor</surname><given-names>AH</given-names></name>, <name><surname>Whitaker</surname><given-names>CW</given-names></name>, <name><surname>Sahai</surname><given-names>R</given-names></name>, <name><surname>Caton</surname><given-names>AJ</given-names></name>. <article-title>Hemagglutinin polymorphism as the basis for low- and high-yield phenotypes of swine influenza virus</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1988</year>;<volume>85</volume>(<issue>20</issue>):<fpage>7782</fpage>&#x02013;<lpage>5</lpage>. <?supplied-pmid 3174662?><pub-id pub-id-type="pmid">3174662</pub-id></mixed-citation></ref><ref id="pone.0199167.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Mandelboim</surname><given-names>M</given-names></name>, <name><surname>Glatman-Freedman</surname><given-names>A</given-names></name>, <name><surname>Drori</surname><given-names>Y</given-names></name>, <name><surname>Sherbany</surname><given-names>H</given-names></name>, <name><surname>Pando</surname><given-names>R</given-names></name>, <name><surname>Sefty</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Ineffectiveness of the 2014&#x02013;2015 H3N2 influenza vaccine</article-title>. <source>Oncotarget</source>. <year>2016</year>;<volume>7</volume>(<issue>2</issue>):<fpage>1185</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.6746</pub-id>
<?supplied-pmid 26716420?><pub-id pub-id-type="pmid">26716420</pub-id></mixed-citation></ref><ref id="pone.0199167.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Sobel Leonard</surname><given-names>A</given-names></name>, <name><surname>McClain</surname><given-names>MT</given-names></name>, <name><surname>Smith</surname><given-names>GJ</given-names></name>, <name><surname>Wentworth</surname><given-names>DE</given-names></name>, <name><surname>Halpin</surname><given-names>RA</given-names></name>, <name><surname>Lin</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>Deep Sequencing of Influenza A Virus from a Human Challenge Study Reveals a Selective Bottleneck and Only Limited Intrahost Genetic Diversification</article-title>. <source>J Virol</source>. <year>2016</year>;<volume>90</volume>(<issue>24</issue>):<fpage>11247</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01657-16</pub-id>
<?supplied-pmid 27707932?><pub-id pub-id-type="pmid">27707932</pub-id></mixed-citation></ref><ref id="pone.0199167.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Jegaskanda</surname><given-names>S</given-names></name>, <name><surname>Job</surname><given-names>ER</given-names></name>, <name><surname>Kramski</surname><given-names>M</given-names></name>, <name><surname>Laurie</surname><given-names>K</given-names></name>, <name><surname>Isitman</surname><given-names>G</given-names></name>, <name><surname>de Rose</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies</article-title>. <source>J Immunol</source>. <year>2013</year>;<volume>190</volume>(<issue>4</issue>):<fpage>1837</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1201574</pub-id>
<?supplied-pmid 23319732?><pub-id pub-id-type="pmid">23319732</pub-id></mixed-citation></ref><ref id="pone.0199167.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Peng</surname><given-names>W</given-names></name>, <name><surname>de Vries</surname><given-names>RP</given-names></name>, <name><surname>Grant</surname><given-names>OC</given-names></name>, <name><surname>Thompson</surname><given-names>AJ</given-names></name>, <name><surname>McBride</surname><given-names>R</given-names></name>, <name><surname>Tsogtbaatar</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Recent H3N2 Viruses Have Evolved Specificity for Extended, Branched Human-type Receptors, Conferring Potential for Increased Avidity</article-title>. <source>Cell Host Microbe</source>. <year>2017</year>;<volume>21</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.11.004</pub-id>
<?supplied-pmid 28017661?><pub-id pub-id-type="pmid">28017661</pub-id></mixed-citation></ref><ref id="pone.0199167.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Koutsakos</surname><given-names>M</given-names></name>, <name><surname>Nguyen</surname><given-names>TH</given-names></name>, <name><surname>Barclay</surname><given-names>WS</given-names></name>, <name><surname>Kedzierska</surname><given-names>K</given-names></name>. <article-title>Knowns and unknowns of influenza B viruses</article-title>. <source>Future Microbiol</source>. <year>2016</year>;<volume>11</volume>(<issue>1</issue>):<fpage>119</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.2217/fmb.15.120</pub-id>
<?supplied-pmid 26684590?><pub-id pub-id-type="pmid">26684590</pub-id></mixed-citation></ref><ref id="pone.0199167.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>D</given-names></name>, <name><surname>Elderfield</surname><given-names>RA</given-names></name>, <name><surname>Barclay</surname><given-names>WS</given-names></name>. <article-title>Molecular studies of influenza B virus in the reverse genetics era</article-title>. <source>J Gen Virol</source>. <year>2011</year>;<volume>92</volume>(<issue>Pt 1</issue>):<fpage>1</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.026187-0</pub-id>
<?supplied-pmid 20926635?><pub-id pub-id-type="pmid">20926635</pub-id></mixed-citation></ref><ref id="pone.0199167.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Burnham</surname><given-names>AJ</given-names></name>, <name><surname>Baranovich</surname><given-names>T</given-names></name>, <name><surname>Govorkova</surname><given-names>EA</given-names></name>. <article-title>Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance</article-title>. <source>Antiviral Res</source>. <year>2013</year>;<volume>100</volume>(<issue>2</issue>):<fpage>520</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.08.023</pub-id>
<?supplied-pmid 24013000?><pub-id pub-id-type="pmid">24013000</pub-id></mixed-citation></ref><ref id="pone.0199167.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Verma</surname><given-names>S</given-names></name>, <name><surname>Soto</surname><given-names>J</given-names></name>, <name><surname>Vasudevan</surname><given-names>A</given-names></name>, <name><surname>Schmeisser</surname><given-names>F</given-names></name>, <name><surname>Alvarado-Facundo</surname><given-names>E</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>4</issue>):<fpage>e0175733</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0175733</pub-id>
<?supplied-pmid 28423025?><pub-id pub-id-type="pmid">28423025</pub-id></mixed-citation></ref><ref id="pone.0199167.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Mogabgab</surname><given-names>WJ</given-names></name>, <name><surname>Green</surname><given-names>IJ</given-names></name>, <name><surname>Dierkhising</surname><given-names>OC</given-names></name>, <name><surname>Phillips</surname><given-names>IA</given-names></name>. <article-title>Isolation and cytopathogenic effect of influenza B viruses in monkey kidney cultures</article-title>. <source>Proc Soc Exp Biol Med</source>. <year>1955</year>;<volume>89</volume>(<issue>4</issue>):<fpage>654</fpage>&#x02013;<lpage>9</lpage>. <?supplied-pmid 13254857?><pub-id pub-id-type="pmid">13254857</pub-id></mixed-citation></ref><ref id="pone.0199167.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Stohr</surname><given-names>K</given-names></name>. <article-title>Influenza&#x02014;WHO cares</article-title>. <source>Lancet Infect Dis</source>. <year>2002</year>;<volume>2</volume>(<issue>9</issue>):<fpage>517</fpage>
<?supplied-pmid 12206966?><pub-id pub-id-type="pmid">12206966</pub-id></mixed-citation></ref><ref id="pone.0199167.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Belongia</surname><given-names>EA</given-names></name>, <name><surname>Skowronski</surname><given-names>DM</given-names></name>, <name><surname>McLean</surname><given-names>HQ</given-names></name>, <name><surname>Chambers</surname><given-names>C</given-names></name>, <name><surname>Sundaram</surname><given-names>ME</given-names></name>, <name><surname>De Serres</surname><given-names>G</given-names></name>. <article-title>Repeated annual influenza vaccination and vaccine effectiveness: review of evidence</article-title>. <source>Expert Rev Vaccines</source>. <year>2017</year>;<volume>16</volume>(<issue>7</issue>):<fpage>1</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="pone.0199167.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Hussain</surname><given-names>M</given-names></name>, <name><surname>Galvin</surname><given-names>HD</given-names></name>, <name><surname>Haw</surname><given-names>TY</given-names></name>, <name><surname>Nutsford</surname><given-names>AN</given-names></name>, <name><surname>Husain</surname><given-names>M</given-names></name>. <article-title>Drug resistance in influenza A virus: the epidemiology and management</article-title>. <source>Infect Drug Resist</source>. <year>2017</year>;<volume>10</volume>:<fpage>121</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.2147/IDR.S105473</pub-id>
<?supplied-pmid 28458567?><pub-id pub-id-type="pmid">28458567</pub-id></mixed-citation></ref><ref id="pone.0199167.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Kemble</surname><given-names>GW</given-names></name>, <name><surname>Bodian</surname><given-names>DL</given-names></name>, <name><surname>Rose</surname><given-names>J</given-names></name>, <name><surname>Wilson</surname><given-names>IA</given-names></name>, <name><surname>White</surname><given-names>JM</given-names></name>. <article-title>Intermonomer disulfide bonds impair the fusion activity of influenza virus hemagglutinin</article-title>. <source>J Virol</source>. <year>1992</year>;<volume>66</volume>(<issue>8</issue>):<fpage>4940</fpage>&#x02013;<lpage>50</lpage>. <?supplied-pmid 1629960?><pub-id pub-id-type="pmid">1629960</pub-id></mixed-citation></ref><ref id="pone.0199167.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Ogata</surname><given-names>N</given-names></name>. <article-title>Inactivation of influenza virus haemagglutinin by chlorine dioxide: oxidation of the conserved tryptophan 153 residue in the receptor-binding site</article-title>. <source>J Gen Virol</source>. <year>2012</year>;<volume>93</volume>(<issue>Pt 12</issue>):<fpage>2558</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.044263-0</pub-id>
<?supplied-pmid 22933663?><pub-id pub-id-type="pmid">22933663</pub-id></mixed-citation></ref><ref id="pone.0199167.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Sriwilaijaroen</surname><given-names>N</given-names></name>, <name><surname>Wilairat</surname><given-names>P</given-names></name>, <name><surname>Hiramatsu</surname><given-names>H</given-names></name>, <name><surname>Takahashi</surname><given-names>T</given-names></name>, <name><surname>Suzuki</surname><given-names>T</given-names></name>, <name><surname>Ito</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities</article-title>. <source>Virol J</source>. <year>2009</year>;<volume>6</volume>:<fpage>124</fpage>
<pub-id pub-id-type="doi">10.1186/1743-422X-6-124</pub-id>
<?supplied-pmid 19678928?><pub-id pub-id-type="pmid">19678928</pub-id></mixed-citation></ref><ref id="pone.0199167.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Sakudo</surname><given-names>A</given-names></name>, <name><surname>Misawa</surname><given-names>T</given-names></name>, <name><surname>Shimizu</surname><given-names>N</given-names></name>, <name><surname>Imanishi</surname><given-names>Y</given-names></name>. N(<article-title>2) gas plasma inactivates influenza virus mediated by oxidative stress</article-title>. <source>Front Biosci (Elite Ed)</source>. <year>2014</year>;<volume>6</volume>:<fpage>69</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">24389143</pub-id></mixed-citation></ref><ref id="pone.0199167.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Sundararajan</surname><given-names>A</given-names></name>, <name><surname>Ganapathy</surname><given-names>R</given-names></name>, <name><surname>Huan</surname><given-names>L</given-names></name>, <name><surname>Dunlap</surname><given-names>JR</given-names></name>, <name><surname>Webby</surname><given-names>RJ</given-names></name>, <name><surname>Kotwal</surname><given-names>GJ</given-names></name>, <etal>et al</etal>
<article-title>Influenza virus variation in susceptibility to inactivation by pomegranate polyphenols is determined by envelope glycoproteins</article-title>. <source>Antiviral Res</source>. <year>2010</year>;<volume>88</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2010.06.014</pub-id>
<?supplied-pmid 20637243?><pub-id pub-id-type="pmid">20637243</pub-id></mixed-citation></ref><ref id="pone.0199167.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Bafort</surname><given-names>F</given-names></name>, <name><surname>Parisi</surname><given-names>O</given-names></name>, <name><surname>Perraudin</surname><given-names>JP</given-names></name>, <name><surname>Jijakli</surname><given-names>MH</given-names></name>. <article-title>Mode of action of lactoperoxidase as related to its antimicrobial activity: a review</article-title>. <source>Enzyme Res</source>. <year>2014</year>;<volume>2014</volume>:<fpage>517164</fpage>
<pub-id pub-id-type="doi">10.1155/2014/517164</pub-id>
<?supplied-pmid 25309750?><pub-id pub-id-type="pmid">25309750</pub-id></mixed-citation></ref><ref id="pone.0199167.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Kordyukova</surname><given-names>LV</given-names></name>, <name><surname>Shtykova</surname><given-names>EV</given-names></name>, <name><surname>Baratova</surname><given-names>LA</given-names></name>, <name><surname>Svergun</surname><given-names>DI</given-names></name>, <name><surname>Batishchev</surname><given-names>OV</given-names></name>. <article-title>Matrix proteins of enveloped viruses: a case study of Influenza A virus M1 protein</article-title>. <source>J Biomol Struct Dyn</source>. <year>2018</year>:<fpage>1</fpage>&#x02013;<lpage>20</lpage>.</mixed-citation></ref><ref id="pone.0199167.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Nagy</surname><given-names>P</given-names></name>, <name><surname>Jameson</surname><given-names>GN</given-names></name>, <name><surname>Winterbourn</surname><given-names>CC</given-names></name>. <article-title>Kinetics and mechanisms of the reaction of hypothiocyanous acid with 5-thio-2-nitrobenzoic acid and reduced glutathione</article-title>. <source>Chem Res Toxicol</source>. <year>2009</year>;<volume>22</volume>(<issue>11</issue>):<fpage>1833</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1021/tx900249d</pub-id>
<?supplied-pmid 19821602?><pub-id pub-id-type="pmid">19821602</pub-id></mixed-citation></ref><ref id="pone.0199167.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Das</surname><given-names>D</given-names></name>, <name><surname>De</surname><given-names>PK</given-names></name>, <name><surname>Banerjee</surname><given-names>RK</given-names></name>. <article-title>Thiocyanate, a plausible physiological electron donor of gastric peroxidase</article-title>. <source>Biochem J</source>. <year>1995</year>;<volume>305</volume> (<issue>Pt 1</issue>):<fpage>59</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">7826354</pub-id></mixed-citation></ref><ref id="pone.0199167.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Higdon</surname><given-names>JV</given-names></name>, <name><surname>Delage</surname><given-names>B</given-names></name>, <name><surname>Williams</surname><given-names>DE</given-names></name>, <name><surname>Dashwood</surname><given-names>RH</given-names></name>. <article-title>Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis</article-title>. <source>Pharmacol Res</source>. <year>2007</year>;<volume>55</volume>(<issue>3</issue>):<fpage>224</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2007.01.009</pub-id>
<?supplied-pmid 17317210?><pub-id pub-id-type="pmid">17317210</pub-id></mixed-citation></ref><ref id="pone.0199167.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Liang</surname><given-names>X</given-names></name>, <name><surname>Feng</surname><given-names>Y</given-names></name>, <name><surname>Lin</surname><given-names>L</given-names></name>, <name><surname>Abeysekera</surname><given-names>IR</given-names></name>, <name><surname>Iqbal</surname><given-names>U</given-names></name>, <name><surname>Wang</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Thyroid function alterations attributed to high iodide supplementation in maternal rats and their offspring</article-title>. <source>J Trace Elem Med Biol</source>. <year>2018</year>;<volume>47</volume>:<fpage>89</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtemb.2018.01.018</pub-id>
<?supplied-pmid 29544812?><pub-id pub-id-type="pmid">29544812</pub-id></mixed-citation></ref><ref id="pone.0199167.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>HS</given-names></name>, <name><surname>Carayanniotis</surname><given-names>G</given-names></name>. <article-title>Induction of goitrous hypothyroidism by dietary iodide in SJL mice</article-title>. <source>Endocrinology</source>. <year>2007</year>;<volume>148</volume>(<issue>6</issue>):<fpage>2747</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1210/en.2007-0082</pub-id>
<?supplied-pmid 17347303?><pub-id pub-id-type="pmid">17347303</pub-id></mixed-citation></ref><ref id="pone.0199167.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Ross</surname><given-names>GR</given-names></name>, <name><surname>Fabersani</surname><given-names>E</given-names></name>, <name><surname>Russo</surname><given-names>M</given-names></name>, <name><surname>Gomez</surname><given-names>A</given-names></name>, <name><surname>Japaze</surname><given-names>H</given-names></name>, <name><surname>Gonzalez</surname><given-names>SN</given-names></name>, <etal>et al</etal>
<article-title>Effect of Excess Iodide Intake on Salivary Glands in a Swiss Albino Mice Model</article-title>. <source>Biomed Res Int</source>. <year>2017</year>;<volume>2017</volume>:<fpage>6302869</fpage>
<pub-id pub-id-type="doi">10.1155/2017/6302869</pub-id>
<?supplied-pmid 29250546?><pub-id pub-id-type="pmid">29250546</pub-id></mixed-citation></ref></ref-list></back></article>